This page ranks high-impact open questions across Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, Frontotemporal Dementia, and Huntington's Disease.[1][3][6][8][10][11]
Priority scoring dimensions:
- Scientific importance: likelihood of resolving causal disease biology.
- Tractability: feasibility with current cohorts, assays, and trial infrastructure.
- Translational impact: potential to change diagnosis, prognosis, or treatment decisions in the next 3 to 5 years.
This update seeds 50 disease-specific open questions and a ranked priority matrix for near-term execution.[2][4][5][7][9][12][13]
Recent multimodal biomarker and pathway studies reinforce near-term opportunities for biological staging, cross-disease stratification, and progression-risk modeling in PD, ALS, FTD, and HD.[14][15][16][17]
Gap scores are generated with python3 scripts/qa_exploration_agent.py gap-analysis and aligned with disease-specific open questions below.
Current cycle source: reports/qa_gap_analysis_2026-03-01T20-36-41Z_ci063.json (generated at 2026-03-01T20:36:46.182811+00:00).
| Topic |
Pages Found |
Gap Score |
Missing Topics |
| alzheimers |
8 |
0 |
None |
| parkinsons |
6 |
0 |
None |
| als |
7 |
0 |
None |
| ftd |
4 |
0 |
None |
| huntingtons |
5 |
0 |
None |
| shallow-topics |
0 |
0 |
parkinsons, als, huntingtons, ftd, neuroinflammation |
| Tier |
Priority Theme |
Scientific Importance |
Tractability |
Translational Impact |
| Tier 1 |
Biological staging before irreversible neurodegeneration |
5 |
4 |
5 |
| Tier 1 |
Validated blood biomarkers for diagnosis and trial enrichment |
5 |
5 |
5 |
| Tier 1 |
Subtype-specific target engagement biomarkers |
5 |
4 |
5 |
| Tier 1 |
Therapy sequencing for disease-modifying combinations |
5 |
3 |
5 |
| Tier 1 |
Presymptomatic intervention frameworks in genetic high-risk cohorts |
5 |
3 |
5 |
| Tier 2 |
Immune and glial mechanism stratification for treatment selection |
4 |
3 |
4 |
| Tier 2 |
Network-level progression models linking molecular and clinical trajectories |
4 |
3 |
4 |
| Tier 2 |
Cross-disease endpoint harmonization for platform trials |
4 |
4 |
4 |
| Tier 2 |
Real-world data integration with biomarker-rich longitudinal cohorts |
4 |
4 |
4 |
| Tier 2 |
Risk prediction tools for prevention and early treatment allocation |
4 |
4 |
4 |
- Which biological subgroup benefits most from anti-amyloid treatment when stratified by baseline plasma p-tau217 and APOE genotype?
- How early does synaptic dysfunction become measurable relative to amyloid and tau positivity in preclinical disease?
- What combination of blood biomarkers best predicts transition from mild cognitive impairment to dementia?
- Which mechanisms drive clinical non-response in amyloid-positive patients receiving monoclonal antibody therapy?
- How should mixed pathology (AD plus vascular or Lewy pathology) alter trial eligibility and endpoint design?
- What is the causal role of microglial state transitions in progression from amyloid accumulation to tau-mediated neurodegeneration?
- Can personalized risk models combining genetics, fluid biomarkers, and imaging improve prevention trial enrichment?
- Which treatment sequence is optimal for amyloid-targeting drugs and downstream tau- or inflammation-targeted therapies?
- How should ARIA risk be managed in APOE4 carriers while preserving treatment effect?
- What are the strongest modifiable systems-level factors that change biologic disease trajectory before symptoms?
- How should alpha-synuclein seed amplification assays be standardized across CSF, blood, and skin sampling platforms?
- Which prodromal individuals have the highest short-term conversion risk when defined by biological staging anchors?
- What are the dominant drivers of selective vulnerability in substantia nigra dopaminergic neurons?
- How early can mitochondrial and lysosomal signatures predict motor versus cognitive progression subtypes?
- Which immune pathways are causally upstream versus downstream of synuclein aggregation?
- How should Gut-Brain Axis hypotheses be tested with prospective mechanistic human cohorts?
- Which biomarker-defined subgroups should be prioritized for disease-modifying trial platforms?
- What are the most reproducible digital endpoints for early-stage disease progression?
- Can combined alpha-synuclein and neuroinflammation biomarkers improve diagnosis of atypical parkinsonism overlap syndromes?
- Which therapeutic combinations are most likely to slow progression in genetically stratified Parkinson populations?
- Which plasma biomarker panels are robust enough for clinical deployment before overt motor symptoms?
- How should presymptomatic gene-carrier cohorts be staged for prevention-oriented intervention trials?
- What is the therapeutic value of targeting non-coding regulatory variation in sporadic ALS?
- How can trial design better account for molecular heterogeneity across SOD1, C9orf72, TARDBP, and FUS biology?
- Which immunological signatures are reproducible and clinically actionable across ALS subtypes?
- How should cell and gene therapies be sequenced with supportive and neuroprotective therapies?
- What biomarkers best forecast bulbar versus limb onset and respiratory decline trajectories?
- How can ALS-FTD spectrum phenotypes be integrated into unified endpoint frameworks?
- Which mechanistic pathways explain resilience in slow-progressing ALS cases?
- What combinations of molecular and digital biomarkers should become standard in platform trials?
- Which biomarkers best discriminate FTLD-TDP from FTLD-tau in early symptomatic patients?
- How should gene-first prevention studies be designed for C9orf72, GRN, and MAPT carriers?
- What is the most tractable route to modifying TDP-43 pathology in sporadic disease?
- How do language-led and behavior-led phenotypes differ in network-level progression biology?
- Which psychosis-associated molecular profiles can guide personalized management in FTD subtypes?
- What biomarkers are most predictive of motor conversion along the FTD-ALS continuum?
- How should multimodal imaging and fluid biomarkers be harmonized for multicenter therapeutic trials?
- Which causal mechanisms link neuroinflammation to region-specific degeneration in FTD?
- How should outcome measures capture caregiver-relevant behavioral improvement in clinical studies?
- What trial-ready subgroups can be defined using genotype and molecular pathology together?
- How can somatic CAG repeat expansion be quantified longitudinally in accessible tissues for trial use?
- Which mismatch-repair targets provide the best efficacy-safety balance for somatic expansion suppression?
- How should therapeutic strategies prioritize huntingtin lowering versus pathway-level downstream rescue?
- What biomarkers best predict transition from premanifest to early manifest Huntington's Disease?
- Which molecular signatures distinguish likely responders to RNA-targeted therapeutics?
- How should combination therapy trials integrate symptomatic and disease-modifying endpoints?
- What mechanistic pathways drive cognitive decline independently of motor progression?
- Which cell-type-specific vulnerabilities should guide next-generation neuroprotective targets?
- How can real-world progression data be harmonized with biomarker-rich trial cohorts?
- What are the highest-value opportunities in the current small-molecule and nucleic acid development pipeline?
This cycle re-ran gap analysis and again identified neuroinflammation as the only named cross-disease gap. This pass adds another trial-readiness set focused on neuroimmune biomarkers that can move from observational cohorts to adaptive studies across Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, Frontotemporal Dementia, and Huntington's Disease[18][19][20][21][22][23].
- Which TSPO-linked CSF proteins can be pre-specified as enrichment biomarkers for anti-inflammatory add-on trials in early Alzheimer's Disease?
- Can combined GFAP, CXCL1, and TNFRSF11B panels improve short-interval response readouts in Alzheimer's Disease platform protocols?
- In prodromal Parkinson's Disease, which inflammation biomarkers are reproducible enough to support adaptive randomization across multicenter cohorts?
- What minimum sampling cadence is needed to detect clinically meaningful neuroimmune state shifts before motor progression milestones in Parkinson's Disease?
- For SOD1-ALS, which rising inflammatory markers during tofersen treatment should trigger escalation or combination-therapy arms?
- Can longitudinal CHI3L1 and NfL trends serve as interim pharmacodynamic gates in ALS umbrella designs?
- Which familial FTD cohorts should be prioritized for standardized fluid neuroimmune biomarker qualification across GRN, MAPT, and C9orf72 carriers?
- How should multicenter FTD studies harmonize sample handling and assay platforms to reduce between-site inflammatory biomarker drift?
- In Huntington's Disease, which compact inflammation-aware secondary endpoint bundle is most feasible for 6-month proof-of-concept studies?
- Which shared neuroinflammation markers can be adopted as cross-disease secondary outcomes for basket-trial comparisons across AD, PD, ALS, FTD, and HD?
This cycle reran gap analysis and neuroinflammation remained the only named cross-disease gap. This pass prioritizes biomarker qualification steps that can support adaptive trial decisions across Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, Frontotemporal Dementia, and Huntington's Disease[24][25][26][27][28][29].
- Which combined GFAP, YKL-40, and synaptic-injury marker panels best forecast near-term decline in preclinical Alzheimer's Disease?
- Can plasma sAxl plus locus coeruleus imaging identify a pragmatic enrichment subset for anti-inflammatory AD studies?
- Which multimodal immune-activation signatures in early Parkinson's Disease are reproducible enough to drive adaptive arm allocation?
- What biomarker thresholds should define biologic response versus non-response in Parkinson's Disease platform protocols?
- For SOD1-ALS, which longitudinal neuroimmune marker trajectories should trigger treatment intensification after tofersen?
- Can a compact ALS fluid panel be standardized across real-world registries to support external control matching in proof-of-concept trials?
- Which subtype-specific CSF signatures in genetic FTD should be prioritized for multicenter analytical validation first?
- How can FTD consortia harmonize pre-analytic handling to reduce between-site drift in inflammatory proteomic readouts?
- Which cytokine set in Huntington's Disease has the strongest evidence for tracking short-interval progression in phase 2 studies?
- What cross-disease neuroimmune biomarker core set is realistic to pre-register as shared secondary endpoints for AD/PD/ALS/FTD/HD basket trials?
This cycle re-ran gap analysis and neuroinflammation remained the only named cross-disease gap. This pass adds a biomarker-readiness update focused on modalities that can support enrollment enrichment, response monitoring, and faster go/no-go decisions across Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, Frontotemporal Dementia, and Huntington's Disease[30][31][32][33][34][35].
- Which plasma marker combinations best predict short-interval conversion to abnormal amyloid PET in preclinical Alzheimer's Disease?
- What operating characteristics should be required before plasma Alzheimer's Disease panels are used as enrichment gates in multicenter anti-inflammatory protocols?
- In de novo Parkinson's Disease, how does APOE epsilon4 status alter baseline immune and network-level biomarker profiles relevant to trial stratification?
- Which Parkinson's Disease biomarker subsets are stable enough over six months to support adaptive randomization triggers?
- For ALS, which joint NfL and pTau trajectories should trigger treatment intensification in platform designs?
- Can motor-neuron-derived epigenetic signatures be standardized as pharmacodynamic markers to complement fluid proteins in ALS studies?
- In FTD, can retinal microvascular phenotypes plus MRI burden improve near-term progression modeling for proof-of-concept trials?
- What minimum multicenter harmonization is needed before retinal and imaging biomarkers are accepted as secondary endpoints in FTD intervention studies?
- In Huntington's Disease, can neuron-derived extracellular vesicle assays provide reproducible short-interval readouts for huntingtin lowering programs?
- Which cross-disease biomarker core set is feasible to pre-register for basket-style neuroinflammation trials spanning AD, PD, ALS, FTD, and HD?
This cycle re-ran gap analysis and neuroinflammation remained the only named cross-disease gap. This pass adds an immune-endophenotyping update focused on tightening enrollment logic and endpoint selection across Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, Frontotemporal Dementia, and Huntington's Disease[36][37][38][39][40][41].
- In preclinical Alzheimer's Disease, which pTau217-based decision thresholds best balance false exclusion versus enrichment in anti-inflammatory prevention trials?
- Should multimarker Alzheimer's Disease entry criteria combine pTau217 with amyloid PET only, or add immune markers to improve event-rate prediction?
- For early Parkinson's Disease, which blood inflammatory signatures are reproducible enough across centers to serve as stratification covariates?
- What assay harmonization standards are needed before inflammatory blood markers can be accepted as secondary endpoints in Parkinson's Disease disease-modification trials?
- In FTD, can in vivo immune activation imaging define responder-enriched subgroups for microglia-targeted studies?
- Which FTD genotypes should be prioritized for immune-intervention basket cohorts based on convergent central immune activation signals?
- Across AD/PD/ALS/FTD/HD, does age-related T-cell state explain variance in treatment response that disease labels alone miss?
- In ALS, can blood STMN2 cryptic-splicing readouts be paired with inflammatory panels to trigger adaptive treatment escalation?
- In Huntington's Disease, what trial windows are optimal for testing microglia-modulating strategies informed by miR-34a biology?
- Which shared cross-disease immune-endophenotype panel is feasible to pre-register for platform protocols spanning AD, PD, ALS, FTD, and HD?
- Convert top Tier 1 items into biomarker-gated platform trial concepts with explicit inclusion criteria.
- Require pre-specified target-engagement biomarkers for all disease-modifying candidates.
- Pair each open question with one measurable milestone, one data source, and one responsible page owner.
- Re-score this matrix quarterly as new phase 2/3 data and biomarker validation studies are published.
This cycle executed python3 scripts/qa_exploration_agent.py gap-analysis and python3 scripts/gap_analysis_agent.py analyze to identify current coverage and mechanism gaps.
- Undercovered diseases detected: 4
- Critical gaps detected: 0
- Prioritized mechanism signal from QA scan: none
- No mechanism-level missing-topic signal exceeded the configured threshold in this cycle.
- Which Parkinson's Disease, Amyotrophic Lateral Sclerosis, Huntington's Disease, and Frontotemporal Dementia subtopics should be expanded first to close page-count deficits?
- Which neuroinflammation biomarkers are currently actionable for cross-disease trial enrichment?
- Which underlinked entities in the neuroinflammation pathway need dedicated pages or deeper references next cycle?
The study of Research Priorities In Neurodegenerative Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Morris et al., The pathogenesis of Parkinson's Disease, Lancet 2024
- Rissardo and Caprara, alpha-synuclein seed amplification assays in Parkinson's Disease 2025
- Plasma phosphorylated tau for Alzheimer's diagnosis, systematic review and meta-analysis 2025
- Wu and Fuh, 2025 update on treatment strategies for the Alzheimer's Disease spectrum
- Blood-based biomarkers for detecting Alzheimer's pathology, meta-analysis 2025
- Paris and Lakatos, Cell and gene therapy for amyotrophic lateral sclerosis 2024
- Moll et al., Non-coding genome contribution to ALS 2024
- Urso et al., Incidence and prevalence of Frontotemporal Dementia 2025
- Woollacott et al., Frontotemporal lobar degeneration primer 2023
- Khan et al., Huntington's Disease drug pipeline review 2025
- Donaldson et al., Huntington's Disease somatic expansion pathobiology therapeutics 2026
- Llibre-Guerra et al., Towards pharmacological prevention of Alzheimer's Disease 2025
- Jimenez-Garcia et al., ALS and FTD gene mutations meta-analysis 2025
- Coughlin et al., alpha-synuclein seed amplification parameters and prodromal Parkinson progression risk 2025
- Chia et al., Plasma proteomics candidate biomarker panel predictive of ALS 2025
- Handsaker et al., Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's Disease 2025
- Ali et al., Shared and disease-specific pathways in FTD, AD, and PD 2025
- Pola I et al., Exploring inflammation-related protein expression and its relationship with TSPO PET in Alzheimer's Disease (2025)
- Martinez-Perez DA et al., Amyloid-Beta plaque-associated microglia drive TSPO upregulation in Alzheimer's Disease (2025)
- Lind-Holm Mogensen F et al., Microglial dynamics and neuroinflammation in prodromal and early Parkinson's Disease (2025)
- Simonini C et al., Neurodegenerative and neuroinflammatory changes in SOD1-ALS patients receiving tofersen (2025)
- Steffke C et al., Targeted proteomics upon treatment with tofersen identifies novel response markers for SOD1-ALS (2025)
- Guo M et al., Fluid biomarkers in familial Frontotemporal Dementia: progress and prospects (2025)
- Muñoz-García A et al., Synaptic dysfunction and glial activation markers throughout aging and early neurodegeneration: a longitudinal CSF biomarker-based study (2025)
- Scott BM et al., Multimodal markers of immune activation predict cognitive outcomes in Parkinson's Disease (2025)
- Sogorb-Esteve A et al., Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic Frontotemporal Dementia subtypes (2025)
- Rocha NP et al., Cytokines as biomarkers of Huntington's Disease progression (2025)
- Smith EF et al., Tofersen treatment leads to sustained stabilization of disease in SOD1 ALS in a real-world setting (2025)
- Galgani A et al., Locus coeruleus integrity correlates with plasma soluble Axl levels in Alzheimer's Disease patients (2025)
- Cogswell PM et al., Plasma Alzheimer's Disease biomarker relationships with incident abnormal amyloid PET (2025)
- Conti M et al., Clinical, biological, and functional connectivity profile of de novo Parkinson disease in APOE epsilon4 carriers (2026)
- Thomas EV et al., ALS plasma biomarkers reveal neurofilament and pTau correlate with disease onset and progression (2025)
- Harvey C et al., Evaluation of a biomarker for amyotrophic lateral sclerosis derived from a hypomethylated DNA signature of human motor neurons (2025)
- Chen Y et al., Retinal microvascular alterations reflect cerebral small vessel disease burden in Frontotemporal Dementia: a multimodal OCTA-MRI study (2025)
- Bras IC et al., Neuron-derived extracellular vesicles in plasma present a potential non-invasive biomarker for huntingtin protein and RNA assessment in Huntington's Disease (2025)
- Singh A et al., Clinical utility and prognostic value of plasma pTau217 in the diagnosis and progression of Alzheimer's Disease (2025)
- Butler L et al., Is there a role for blood-based inflammatory biomarkers in Parkinson's Disease? (2025)
- Pereira M et al., Central nervous system immune activation in Frontotemporal Dementia due to C9orf72 mutations and sporadic disease (2024)
- Thevanayagam H et al., A broad anti-inflammatory switch in neurodegeneration with brain T-cell aging (2024)
- Pape K et al., STMN2 cryptic splicing in blood predicts ALS disease progression and survival (2024)
- Mottin M et al., MiR-34a regulates inflammatory microglia and disease progression in Huntington's Disease (2024)